Article Sidebar

PDF
Date Published: 23/12/2021
Abstract Views: 434
Views PDF: 205
DOI: https://doi.org/10.51298/vmj.v507i2.1410
Issue
Vol. 507 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Duyên, N. ., & Tuấn Anh, B. . (2021). PLASMA IL-6 LEVEL AND HOMA2-IR INDEX IN TYPE 2 DIABETES PAINTIENTS. Vietnam Medical Journal, 507(2). https://doi.org/10.51298/vmj.v507i2.1410

PLASMA IL-6 LEVEL AND HOMA2-IR INDEX IN TYPE 2 DIABETES PAINTIENTS

Nguyễn Thị Duyên1,, Bùi Tuấn Anh1
1 Bach Mai Hospital

Main Article Content

Abstract

Type 2 diabetes mellitus (T2DM) has been one ot the most concerned health  problem globally. T2DM has a complex pathogenesis including insulin resistance. HOMA2-IR is a tool used for objective and non-invasive assessment of insulin resistance. Interleukin-6 is a cytokine related to obesity and insulin resistance in T2DM patients. In this study, we calculated HOMA2-IR index and measured IL-6 level of T2DM patients to compare with healthy control group and analyze the relation. Result: HOMA2-IR index in disease group was 2.92 ±1.75 and that of healthy control group was 1.52±0.68; while plasma IL-6 level in disease group was 3.15±2.19 pg/ml and control group was 1.85±0,91 pg/mL with p<0.05. There was a  proportional moderate relation betwwen plasma IL-6 level and HOMA2-IR index with r=0.569, p<0.01. Conclusion: There was a statistically significane in the difference between HOMA2-IR index and plasma IL-6 level of disease group and control group.

Article Details

Keywords

Type 2 diabetes mellitus (T2DM), plasma IL-6 level, HOMA2-IR index

References

1. Freeman AM, Pennings N. Insulin Resistance. In: StatPearls. StatPearls Publishing; 2021. Accessed July 31, 2021. http://www.ncbi.nlm.nih.gov/books/NBK507839/
2. Inchiostro S. Measurement of insulin sensitivity in Type 2 diabetes mellitus: comparison between KITT and HOMA-% S indices and evaluation of their relationship with the components of the insulin resistance syndrome. Diabetic medicine. 2005;22(1):39-44.
3. Lehrskov LL, Christensen RH. The role of interleukin-6 in glucose homeostasis and lipid metabolism. Semin Immunopathol. 2019;41(4): 491-499. doi:10.1007/s00281-019-00747-2
4. Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26(3):685-698. doi:10.1007/s10787-018-0458-0
5. Marques-Vidal P, Bastardot F, von Känel R, et al. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol (Oxf). 2013; 78(2):232-241. doi:10.1111/j.1365-2265.2012.04384.x
6. Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF-α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects. N Am J Med Sci. 2012;4(4):180-184. doi:10.4103/1947-2714.94944
7. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745-751. doi:10.1152/ajpendo.2001.280.5.E745